224 related articles for article (PubMed ID: 25322923)
1. Tolerability and safety of Souvenaid in patients with mild Alzheimer's disease: results of multi-center, 24-week, open-label extension study.
Olde Rikkert MG; Verhey FR; Blesa R; von Arnim CA; Bongers A; Harrison J; Sijben J; Scarpini E; Vandewoude MF; Vellas B; Witkamp R; Kamphuis PJ; Scheltens P
J Alzheimers Dis; 2015; 44(2):471-80. PubMed ID: 25322923
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of Souvenaid in mild Alzheimer's disease: results from a randomized, controlled trial.
Scheltens P; Twisk JW; Blesa R; Scarpini E; von Arnim CA; Bongers A; Harrison J; Swinkels SH; Stam CJ; de Waal H; Wurtman RJ; Wieggers RL; Vellas B; Kamphuis PJ
J Alzheimers Dis; 2012; 31(1):225-36. PubMed ID: 22766770
[TBL] [Abstract][Full Text] [Related]
3. Effects of Souvenaid on plasma micronutrient levels and fatty acid profiles in mild and mild-to-moderate Alzheimer's disease.
Rijpma A; Meulenbroek O; van Hees AM; Sijben JW; Vellas B; Shah RC; Bennett DA; Scheltens P; Olde Rikkert MG
Alzheimers Res Ther; 2015; 7(1):51. PubMed ID: 26213579
[TBL] [Abstract][Full Text] [Related]
4. The medical food Souvenaid affects brain phospholipid metabolism in mild Alzheimer's disease: results from a randomized controlled trial.
Rijpma A; van der Graaf M; Lansbergen MM; Meulenbroek O; Cetinyurek-Yavuz A; Sijben JW; Heerschap A; Olde Rikkert MGM
Alzheimers Res Ther; 2017 Jul; 9(1):51. PubMed ID: 28747210
[TBL] [Abstract][Full Text] [Related]
5. Effect Size Analyses of Souvenaid in Patients with Alzheimer's Disease.
Cummings J; Scheltens P; McKeith I; Blesa R; Harrison JE; Bertolucci PH; Rockwood K; Wilkinson D; Wijker W; Bennett DA; Shah RC
J Alzheimers Dis; 2017; 55(3):1131-1139. PubMed ID: 27767993
[TBL] [Abstract][Full Text] [Related]
6. The effect of souvenaid on functional brain network organisation in patients with mild Alzheimer's disease: a randomised controlled study.
de Waal H; Stam CJ; Lansbergen MM; Wieggers RL; Kamphuis PJ; Scheltens P; Maestú F; van Straaten EC
PLoS One; 2014; 9(1):e86558. PubMed ID: 24475144
[TBL] [Abstract][Full Text] [Related]
7. Nutritional approaches in the risk reduction and management of Alzheimer's disease.
Mi W; van Wijk N; Cansev M; Sijben JW; Kamphuis PJ
Nutrition; 2013 Sep; 29(9):1080-9. PubMed ID: 23756280
[TBL] [Abstract][Full Text] [Related]
8. The efficacy of supplementation with the novel medical food, Souvenaid, in patients with Alzheimer's disease: A systematic review and meta-analysis of randomized clinical trials.
Onakpoya IJ; Heneghan CJ
Nutr Neurosci; 2017 May; 20(4):219-227. PubMed ID: 26638900
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of a medical food in mild Alzheimer's disease: A randomized, controlled trial.
Scheltens P; Kamphuis PJ; Verhey FR; Olde Rikkert MG; Wurtman RJ; Wilkinson D; Twisk JW; Kurz A
Alzheimers Dement; 2010 Jan; 6(1):1-10.e1. PubMed ID: 20129316
[TBL] [Abstract][Full Text] [Related]
10. A randomized, double-blind, placebo-controlled, 16-week study of the H3 receptor antagonist, GSK239512 as a monotherapy in subjects with mild-to-moderate Alzheimer's disease.
Grove RA; Harrington CM; Mahler A; Beresford I; Maruff P; Lowy MT; Nicholls AP; Boardley RL; Berges AC; Nathan PJ; Horrigan JP
Curr Alzheimer Res; 2014 Jan; 11(1):47-58. PubMed ID: 24359500
[TBL] [Abstract][Full Text] [Related]
11. The S-Connect study: results from a randomized, controlled trial of Souvenaid in mild-to-moderate Alzheimer's disease.
Shah RC; Kamphuis PJ; Leurgans S; Swinkels SH; Sadowsky CH; Bongers A; Rappaport SA; Quinn JF; Wieggers RL; Scheltens P; Bennett DA
Alzheimers Res Ther; 2013; 5(6):59. PubMed ID: 24280255
[TBL] [Abstract][Full Text] [Related]
12. Long-term safety and efficacy of donepezil in patients with severe Alzheimer's disease: results from a 52-week, open-label, multicenter, extension study in Japan.
Homma A; Imai Y; Tago H; Asada T; Shigeta M; Iwamoto T; Takita M; Arimoto I; Koma H; Takase T; Ohbayashi T
Dement Geriatr Cogn Disord; 2009; 27(3):232-9. PubMed ID: 19246907
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of donepezil over 3 years: an open-label, multicentre study in patients with Alzheimer's disease.
Burns A; Gauthier S; Perdomo C
Int J Geriatr Psychiatry; 2007 Aug; 22(8):806-12. PubMed ID: 17199235
[TBL] [Abstract][Full Text] [Related]
14. Open label, multicenter, 28-week extension study of the safety and tolerability of memantine in patients with mild to moderate Alzheimer's disease.
Ott BR; Blake LM; Kagan E; Resnick M;
J Neurol; 2007 Mar; 254(3):351-8. PubMed ID: 17345042
[TBL] [Abstract][Full Text] [Related]
15. The LipiDiDiet trial: what does it add to the current evidence for Fortasyn Connect in early Alzheimer's disease?
Rasmussen J
Clin Interv Aging; 2019; 14():1481-1492. PubMed ID: 31616139
[TBL] [Abstract][Full Text] [Related]
16. Souvenaid®: a new approach to management of early Alzheimer's disease.
Ritchie CW; Bajwa J; Coleman G; Hope K; Jones RW; Lawton M; Marven M; Passmore P
J Nutr Health Aging; 2014 Mar; 18(3):291-9. PubMed ID: 24626757
[TBL] [Abstract][Full Text] [Related]
17. Assessment of a Potential Synergistic Effect of Souvenaid® in Mild Alzheimer's Disease Patients on Treatment with Acetylcholinesterase Inhibitors: An Observational, Non-Interventional Study.
Viñuela F; Barro A
J Alzheimers Dis; 2021; 80(4):1377-1382. PubMed ID: 33682712
[TBL] [Abstract][Full Text] [Related]
18. Magnetoencephalography for the Detection of Intervention Effects of a Specific Nutrient Combination in Patients with Mild Alzheimer's Disease: Results from an Exploratory Double-Blind, Randomized, Controlled Study.
van Straaten EC; de Waal H; Lansbergen MM; Scheltens P; Maestu F; Nowak R; Hillebrand A; Stam CJ
Front Neurol; 2016; 7():161. PubMed ID: 27799918
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of Cerebrolysin in moderate to moderately severe Alzheimer's disease: results of a randomized, double-blind, controlled trial investigating three dosages of Cerebrolysin.
Alvarez XA; Cacabelos R; Sampedro C; Aleixandre M; Linares C; Granizo E; Doppler E; Moessler H
Eur J Neurol; 2011 Jan; 18(1):59-68. PubMed ID: 20500802
[TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of galantamine (Reminyl) in severe Alzheimer's disease (the SERAD study): a randomised, placebo-controlled, double-blind trial.
Burns A; Bernabei R; Bullock R; Cruz Jentoft AJ; Frölich L; Hock C; Raivio M; Triau E; Vandewoude M; Wimo A; Came E; Van Baelen B; Hammond GL; van Oene JC; Schwalen S
Lancet Neurol; 2009 Jan; 8(1):39-47. PubMed ID: 19042161
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
